Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 14/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | CTSA | P10619 | 3/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927199 | 0.85 | CHRM1 (0.48) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL5926663 | 0.79 | CTSA (0.53) | CTSACYP26A1 | |
| SCHEMBL5927087 | 0.77 | CYP26A1 (0.49) | CTSACYP26A1 | |
| SCHEMBL5927213 | 0.76 | CTSA (0.52) | CTSACYP26A1MAPT | |
| SCHEMBL5926904 | 0.76 | CTSA (0.50) | CTSACYP26A1MAPT | |
| SCHEMBL5926688 | 0.75 | CTSA (0.58) | CTSACYP26A1 | |
| SCHEMBL5927580 | 0.74 | CTSA (0.43) | CTSACYP26A1 | |
| SCHEMBL5926999 | 0.73 | CTSA (0.61) | CTSACYP26A1 | |
| SCHEMBL5926305 | 0.73 | CYP26A1 (0.44) | CTSACYP26A1 | |
| SCHEMBL5926316 | 0.72 | CNR1 (0.42) | CTSACYP26A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CHRM1 2567/4885CHRM2 2156/4885CHRM4 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.